NeuroScientific Biopharmaceuticals is banking on its new, well-credentialled Perth-based chief medical officer to help the company roll out its innovative stem cell therapy.

NeuroScientific Biopharmaceuticals has snagged a well-credentialled WA haematologist and oncologist as its chief medical officer. The company is banking on Dr Catherine Cole’s decades of clinical ...

The global allogeneic cell therapy market is set to witness a growth rate of 25% in the next 5 years. Growing demand for off-the-shelf therapies; advancements in cell engineering and genomic ...

Imagine your immune cells could be modified to attack any kind of cancer. T cell receptor (TCR) therapy has the potential to one day become a universal cancer treatment. But there are risks ...

Tulsi Therapeutics achieves groundbreaking success in animal trial for liver disease treatment, paving way for human trials.

A team of Memorial Sloan Kettering Cancer Center (MSK) researchers have made an important finding about why genetically engineered immune cells sometimes fail to finish the job when given as a ...

According to the press release, the presentation will highlight the company’s novel first-in-class logic-gated CAR-NK cell therapy, which is designed to kill leukemic cells while protecting ...

The therapy is an autologous CD19 CAR T cell treatment with a proprietary design intended to mimic physiological T-cell receptor interactions.

Team of Chinese medical experts says they can produce anticancer cells directly inside the human body using gene therapy tools.

Capricor Therapeutics said the FDA asked for more data supporting the efficacy of Deramiocel, the biotech’s off-the-shelf cell therapy for treating the heart complications of Duchenne muscular ...